Epidemiol Health.
2021;43(1):e2021097. 10.4178/epih.e2021097.
Real-world incidence of endopthalmitis after intravitreal anti-VEGF injections in Korea: findings from the Common Data Model in ophthalmology
- Mun Y
1 - You SC2
- Lee DY3
- Kim S4
- Chung YR5
- Lee K5
- Song JH5
- Park YG6
- Park YH6
- Roh YJ7
- Woo SJ3
- Park KH3
- Park RW8
- Yoo S4
- Chang DJ7
- Park SJ3
- Affiliations
-
- 1Department of Ophthalmology, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea
- 2Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea
- 3Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
- 4Healthcare Information & Communications Technology (ICT) Research Center, Office of eHealth Research and Businesses, Seoul National University Bundang Hospital, Seongnam, Korea
- 5Department of Ophthalmology, Ajou University School of Medicine, Suwon, Korea
- 6Department of Ophthalmology and Visual Science, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 7Eye Hospital, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 8Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea
- KMID: 2526551
- DOI: http://doi.org/10.4178/epih.e2021097
Abstract
OBJECTIVES
The aim of this study was to evaluate the real-world incidence of endophthalmitis after intravitreal anti-vascular endothelial growth factor (VEGF) injections using data from the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM).
METHODS
Patients with endophthalmitis that developed within 6 weeks after intravitreal anti-VEGF injections were identified in 3 large OMOP CDM databases.
RESULTS
We identified 23,490 patients who received 128,123 intravitreal anti-VEGF injections. The incidence rates of endophthalmitis were 15.75 per 10,000 patients and 2.97 per 10,000 injections. The incidence rates of endophthalmitis for bevacizumab, ranibizumab, and aflibercept (per 10,000 injections) were 3.64, 1.39, and 0.76, respectively. The annual incidence has remained below 5.00 per 10,000 injections since 2011 despite the increasing number of intravitreal anti-VEGF injections. Bevacizumab presented a higher incidence rate for endophthalmitis than ranibizumab and aflibercept (incidence rate ratio, 3.17; p=0.021).
CONCLUSIONS
The incidence of endophthalmitis after intravitreal anti-VEGF injections has stabilized since 2011 despite the explosive increase in anti-VEGF injections. The off-label use of bevacizumab accounted for its disproportionately high incidence of endophthalmitis. The OMOP CDM, which includes off-label uses, laboratory data, and a scalable standardized database, could provide a novel strategy to reveal real-world evidence, especially in ophthalmology.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Real-World Treatment Intensity and Patterns in Patients With Myopic Choroidal Neovascularization: Common Data Model in Ophthalmology
- Incidence of Acute Endophthalmitis after Intravitreal Antivascular Endothelial Growth Factor Injection in Age-related Macular Degeneration
- Intravitreal injection of anti-vascular endothelial growth factor for patients with various retinal diseases
- Resolution of Extensive Exudative Retinal Detachment after Gamma-Knife® Radiosurgery for Refractory Diffuse Choroidal Hemangioma: Case Report
- Comparison of Intravitreal Bevacizumab and Ranibizumab Injections in Aggressive and Type 1 Retinopathy of Prematurity
